Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)

NCT02735083 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02735083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 10, 2021
Completion date
September 30, 2028
Enrollment
28 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoid leukemia